Schrodinger Inc

NASDAQ:SDGRUnited States

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Contact Information

Headquarters

1540 BROADWAY, 24TH FLOORNEW YORK, NY, United States 10036

Phone

503-299-1150

Fax

302-655-5049

Executives

Independent Director

Michael Lynton

President, Chief Executive Officer, Director

Ramy Farid

Chief Financial Officer, Executive Vice President

Geoffrey Porges

President - R&D Therapeutics

Karen Akinsanya

Executive Vice President, Chief Technology Officer

Kenneth Lorton